Literature DB >> 15356160

Protection against late-onset AIDS in macaques prophylactically immunized with a live simian HIV vaccine was dependent on persistence of the vaccine virus.

Glenn A Mackay1, Zhenqian Liu, Dinesh K Singh, Marilyn S Smith, Sampa Mukherjee, Darlene Sheffer, Fenglan Jia, Istvan Adany, Kelvin H Sun, Sukhbir Dhillon, Wu Zhuge, Opendra Narayan.   

Abstract

This is a 5-year follow-up study on 12 macaques that were immunized orally with two live SHIV vaccines, six with V1 and six with V2. All 12 macaques became persistently infected after transient replication of the vaccine viruses; all were challenged vaginally 6 mo later with homologous pathogenic SHIV(KU-1). Two of the V1 group developed full-blown AIDS without evidence of vaccine virus DNA in tissues. The data on the 10 vaccinated survivors showed that all 10 became infected with SHIV(KU-1) and that DNA of both vaccine and SHIV(KU-1) viruses were present 6 mo postchallenge, with minimal replication of SHIV(KU-1). During the following 5 years, these animals remained persistently infected, but with only one of the two viruses. Six animals eliminated their vaccine virus after variable periods of time and four of these succumbed to reactivation of the challenge virus and AIDS. Five years after challenge, four latently infected animals, two with V2 and two with SHIV(KU-1), were reinoculated with SHIV(KU-1.) This resulted in transient superinfection and the animals promptly returned to their prechallenge status. Immunosuppression of the four animals 1 year later with Abs to CD8+ lymphocytes resulted in transiently productive replication of their respective latent viruses, and upon recovery of CD8+ lymphocytes, they reverted to their latent virus status. The major finding was that of eight animals that eliminated the vaccine virus, six developed AIDS. The two others harboring SHIV(KU-1) remain at risk for developing late-onset disease. The primary correlate against AIDS was persistence of the vaccine virus. Copyright 2004 The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356160     DOI: 10.4049/jimmunol.173.6.4100

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Protection of macaques against AIDS with a live attenuated SHIV vaccine is of finite duration.

Authors:  Anil Kumar; Zhenqian Liu; Darlene Sheffer; Marilyn Smith; Dinesh K Singh; Shilpa Buch; Opendra Narayan
Journal:  Virology       Date:  2007-11-07       Impact factor: 3.616

2.  Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines.

Authors:  Jodi K Craigo; Shannon Durkin; Timothy J Sturgeon; Tara Tagmyer; Sheila J Cook; Charles J Issel; Ronald C Montelaro
Journal:  Vaccine       Date:  2006-09-22       Impact factor: 3.641

3.  A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS.

Authors:  Dinesh K Singh; Zhenqian Liu; Darlene Sheffer; Glenn A Mackay; Marilyn Smith; Sukhbir Dhillon; Ramakrishna Hegde; Fenglan Jia; Istvan Adany; Opendra Narayan
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  Morphine potentiates neuropathogenesis of SIV infection in rhesus macaques.

Authors:  Sirosh M Bokhari; Ramakrishna Hegde; Shannon Callen; Honghong Yao; Istvan Adany; Qingsheng Li; Zhuang Li; David Pinson; Hung-Wen Yeh; Paul D Cheney; Shilpa Buch
Journal:  J Neuroimmune Pharmacol       Date:  2011-03-24       Impact factor: 4.147

5.  Longitudinal study to assess the safety and efficacy of a live-attenuated SHIV vaccine in long term immunized rhesus macaques.

Authors:  Thomas M Yankee; Darlene Sheffer; Zhengian Liu; Sukhbir Dhillon; Fenglan Jia; Yahia Chebloune; Edward B Stephens; Opendra Narayan
Journal:  Virology       Date:  2008-11-05       Impact factor: 3.616

6.  SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development?

Authors:  Robert Sealy; Xiaoyan Zhan; Timothy D Lockey; Louis Martin; James Blanchard; Vicki Traina-Dorge; Julia L Hurwitz
Journal:  Curr HIV Res       Date:  2009-09       Impact factor: 1.581

7.  Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge.

Authors:  John Schell; Nina F Rose; Nicole Fazo; Preston A Marx; Meredith Hunter; Elizabeth Ramsburg; David Montefiori; Patricia Earl; Bernard Moss; John K Rose
Journal:  Vaccine       Date:  2009-01-07       Impact factor: 3.641

8.  Limited dissemination of pathogenic SIV after vaginal challenge of rhesus monkeys immunized with a live, attenuated lentivirus.

Authors:  Mars Stone; Zhong-Min Ma; Meritxell Genescà; Linda Fritts; Shelley Blozois; Michael B McChesney; Christopher J Miller
Journal:  Virology       Date:  2009-08-03       Impact factor: 3.616

9.  Effect of morphine on the neuropathogenesis of SIVmac infection in Indian Rhesus Macaques.

Authors:  Joanne K Marcario; Mariam Riazi; Istvan Adany; Himanshu Kenjale; Kandace Fleming; Janet Marquis; Olga Nemon; Matthew S Mayo; Thomas Yankee; Opendra Narayan; Paul D Cheney
Journal:  J Neuroimmune Pharmacol       Date:  2007-09-13       Impact factor: 4.147

Review 10.  Therapeutic immunization for HIV.

Authors:  Lindvi Gudmundsdotter; Anna Sjödin; Ann-Charlotte Boström; Bo Hejdeman; Rebecca Theve-Palm; Annette Alaeus; Knut Lidman; Britta Wahren
Journal:  Springer Semin Immunopathol       Date:  2006-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.